SoniaSinghMD(She/Her)

Medical Officer at FDA, Division of Oncology 2 in the Office of Oncologic Diseases

Dr. Singh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2013
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2015 - 2018
New York Presbyterian Hospital (Cornell Campus)Internship, Pediatrics, 2012 - 2013
Drexel University College of MedicineClass of 2012

PubMed

2 citations
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
Sonia Singh, Diana Bradford, Xiaoxue Li, Pallavi S Mishra-Kalyani, Yuan-Li Shen
Clinical Cancer Research. 2024-01-05
46 citations
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer
Sonia Singh, Adnan A. Jaigirdar, Flora Mulkey, Joyce Cheng, Salaheldin S. Hamed
Clinical Cancer Research. 2021-05-01
9 citations
Esophageal cancer as initial presentation of Fanconi anemia in patients with a hypomorphic FANCA variant.
Francis P. Lach, Sonia Singh, Kimberly A. Rickman, Penelope D. Ruiz, Raymond J. Noonan
Cold Spring Harbor Molecular Case Studies. 2020-12-17

Journal Articles

Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United St...
Fisher B, Singh S, Huang Y, Li Y, Gregory J, Walker D, Seif A, Kavcic M, Aplenc R, Pediatric Blood and Cancer, 7/18/2013